Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery.


Journal

European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772

Informations de publication

Date de publication:
Jan 2022
Historique:
pubmed: 16 3 2021
medline: 21 1 2022
entrez: 15 3 2021
Statut: ppublish

Résumé

To describe the use of intracameral recombinant tissue plasminogen activator (r-tPA) in the treatment of severe fibrinous reactions in toxic anterior segment syndrome (TASS) after cataract surgery. A case series of 59 eyes of 59 patients with severe fibrinous anterior chamber reaction following cataract surgery who received intracameral r-tPA (25 µg/0.1 ml). The main outcome measures after intracameral r-tPA were the incidence of complete fibrinolysis, time of maximal effect, visual acuity, and complications. Severe fibrinous reactions appeared 11.5 ± 5.3 days after cataract surgery. Fibrinolysis was observed 2.33 ± 2.70 days after rtPA use and 36 eyes (61%) exhibited resolution of the fibrin by the end of the first day following injection ( The application of r-tPA was a quick and efficacious therapeutic approach for the management of severe fibrinous reactions in TASS after cataract surgery. In a clinical setting, intracameral r-tPA may be useful when rapid visual recovery is needed.

Sections du résumé

BACKGROUND BACKGROUND
To describe the use of intracameral recombinant tissue plasminogen activator (r-tPA) in the treatment of severe fibrinous reactions in toxic anterior segment syndrome (TASS) after cataract surgery.
METHODS METHODS
A case series of 59 eyes of 59 patients with severe fibrinous anterior chamber reaction following cataract surgery who received intracameral r-tPA (25 µg/0.1 ml). The main outcome measures after intracameral r-tPA were the incidence of complete fibrinolysis, time of maximal effect, visual acuity, and complications.
RESULTS RESULTS
Severe fibrinous reactions appeared 11.5 ± 5.3 days after cataract surgery. Fibrinolysis was observed 2.33 ± 2.70 days after rtPA use and 36 eyes (61%) exhibited resolution of the fibrin by the end of the first day following injection (
CONCLUSIONS CONCLUSIONS
The application of r-tPA was a quick and efficacious therapeutic approach for the management of severe fibrinous reactions in TASS after cataract surgery. In a clinical setting, intracameral r-tPA may be useful when rapid visual recovery is needed.

Identifiants

pubmed: 33719630
doi: 10.1177/11206721211002064
doi:

Substances chimiques

Fibrinolytic Agents 0
Recombinant Proteins 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-204

Auteurs

Perach Osaadon (P)

Ophthalmology Department, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Nadav Belfair (N)

Ophthalmology Department, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Itay Lavy (I)

Ophthalmology Department, Hadassah Medical Center, Jerusalem, Israel.

Eyal Walter (E)

Ophthalmology Department, Hadassah Medical Center, Jerusalem, Israel.

Jaime Levy (J)

Ophthalmology Department, Hadassah Medical Center, Jerusalem, Israel.

Raimo Tuuminen (R)

Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.
Eye Centre, Kymenlaakso Central Hospital, Kotka, Kymenlaakso, Finland.

Asaf Achiron (A)

Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Boris Knyazer (B)

Ophthalmology Department, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH